Daniela Zackova

Head physician, consultant

University Hospital Brno

Czech Republic

Research Interests

Explore related searches

Professors in Cancer Biology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (7)

Jan Zuna

Charles University

CZECH REPUBLIC

View details

Nicholas Cross

Professor of Human Genetics

University of Southampton

UNITED KINGDOM

View details

Hana Zizkova

Institute of Hematology and Transfusion Medicine

CZECH REPUBLIC

View details

DOLORS COLOMER

Associate Professor

University of Barcelona

SPAIN

View details

Ivana Jeziskova

University Hospital Brno

CZECH REPUBLIC

View details

Johan Richter

Professor

Lund University

SWEDEN

View details

Adéla Benešová

Institute of Hematology and Transfusion Medicine

CZECH REPUBLIC

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Daniela Zackova

Research Interests

Explore related searches

Contact this professor

Articles (10)

Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data

Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes

Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF

Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia

Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI

Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice

What is the optimal dose of tyrosine kinase inhibitors in chronic myeloid leukaemia?,Jaké dávky inhibitorů tyrozinkináz jsou v léčbĕ pacientů s chronickou myeloidní leukemií optimální?

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission

Collaborators (7)

Jan Zuna

Nicholas Cross

Hana Zizkova

DOLORS COLOMER

Ivana Jeziskova

Johan Richter

Adéla Benešová

Make your next move.